PDLIM7 and lymphoproliferative syndrome: This finding was considerably different from findings in previous studies, where PD‐L1 expression in tumor cells was observed in 26% of DLBCL, NOS cases examined with immunohistochemistry.18 The frequent up‐regulation of PD‐L1 was also shown in EBV+ post‐transplant lymphoproliferative disorders and EBV+ DLBCL.30, 35, 36 EBV was reported to provide an intrinsic signal to augment PD‐L1 expression through EBV‐LMP1 increasing PD‐L1 promoter and enhancer activity.35 In this study, none of EBV+ gDLBCL cases expressed PD‐L1 on tumor cells, although LMP1 was positive in 7 of 14 EBV+ cases evaluated.